Viedoc Technologies
EClinical Systems for Clinical Trials
The Montreal Heart Institute (MHI) has announced positive, clinically persuasive results from the COLCORONA clinical trial of orally administered drug, colchicine, for treating Covid-19.
The Montreal Heart Institute (MHI) has announced positive, clinically persuasive results from the COLCORONA clinical trial of orally administered drug, colchicine, for treating Covid-19.
The contact-less, randomised, double-blind, placebo-controlled clinical trial was conducted in an at-home setting in Canada, US, Europe, South America and South Africa.
It analysed whether colchicine could lower the risk of severe complications linked to Covid-19.
COLCORONA had approximately 4,500 Covid-19 patients who were not hospitalised at the time of enrolment and had minimum of one risk factor for Covid-19 complications.
According to the study results obtained from 4,488 patients, colchicine lowered the risk of death or hospitalisations by 21% in Covid-19 patients versus placebo, approaching statistical significance.
Furthermore, the analysis of the 4,159 Covid-19 patients receiving colchicine showed statistically significant reductions in the risk of death or hospitalisation versus placebo.
In these Covid-19 patients, the drug lowered hospitalisations by 25%, the requirement for mechanical ventilation by 50% and deaths by 44%.
The Institute noted that the latest scientific discovery makes colchicine the world’s first oral drug which can be used for treating non-hospitalised Covid-19 patients.
MHI Research Center Director, Université de Montréal Medicine professor and COLCORONA trial principal investigator Dr Jean-Claude Tardif said: “Our research shows the efficacy of colchicine treatment in preventing the ‘cytokine storm’ phenomenon and reducing the complications associated with Covid-19.
GlobalData's TMT Themes 2021 Report tells you everything you need to know about disruptive tech themes and which companies are best placed to help you digitally transform your business.
Find out more“We are pleased to offer the first oral medication in the world whose use could have a significant impact on public health and potentially prevent Covid-19 complications for millions of patients.
“Our innovative research programme also proves that the Montreal Heart Institute can make rapid scientific breakthroughs in a way that is economically viable for patients by repurposing existing drugs.
Colchicine treatment can aid in alleviating hospital congestion and cut down healthcare costs, the Institute noted.
EClinical Systems for Clinical Trials
SaaS Platform Decentralizing Clinical Research at Scale
Standardized Tools for Cellular Immune Assays